Ovid Therapeutics Ownership | Who Owns Ovid Therapeutics?

Overview Forecast RevenueFinancials Chart

Ovid Therapeutics Ownership Summary

Ovid Therapeutics is owned by 37.12% institutional investors, 16.31% insiders, and 46.57% retail investors. Takeda pharmaceutical is the largest institutional shareholder, holding 10.61% of OVID shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.52% of its assets in Ovid Therapeutics shares.

OVID Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Ovid Therapeutics	37.12%	16.31%	46.57%
Sector	Healthcare Stocks	279.15%	10.63%	-189.78%
Industry	Biotech Stocks	63.94%	10.67%	25.38%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Takeda pharmaceutical	7.53M	10.61%	$7.01M
Rubric capital management lp	5.32M	7.49%	$4.96M
Blackrock	3.99M	5.65%	$3.07M
Blackrock funding, inc. /de	3.93M	5.54%	$3.67M
Bvf inc/il	3.85M	5.43%	$3.60M
Madison avenue partners, lp	3.72M	5.24%	$3.48M
Vanguard group	3.15M	4.44%	$2.94M
Artal group	2.50M	3.54%	$1.92M
Acadian asset management	1.85M	2.61%	$1.73M
Kennedy capital management	1.55M	2.18%	$1.44M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Takeda pharmaceutical	7.53M	26.40%	$7.01M
Tls advisors	680.97K	1.45%	$636.00K
Madison avenue partners, lp	3.72M	0.37%	$3.48M
Sio capital management	1.00M	0.26%	$933.70K
Bvf inc/il	3.85M	0.12%	$3.60M
Rubric capital management lp	5.32M	0.06%	$4.96M
Velan capital investment management lp	70.00K	0.06%	$65.36K
Artal group	2.50M	0.05%	$1.92M
Kennedy capital management	1.55M	0.03%	$1.44M
Adar1 capital management	130.53K	0.02%	$121.88K

Top Buyers

Holder	Shares	% Assets	Change
Driehaus capital management	1.40M	0.01%	1.40M
Adage capital partners gp	1.00M	0.00%	1.00M
Sio capital management	1.00M	0.26%	1.00M
State street	1.35M	-	198.72K
Adar1 capital management	130.53K	0.02%	92.79K

Top Sellers

Holder	Shares	% Assets	Change
Ecor1 capital	-	-	-6.12M
Siren	-	-	-2.85M
Ubs oconnor	-	-	-943.42K
Blue owl capital lp	-	-	-864.82K
Prosight management, lp	-	-	-729.21K

New Positions

Holder	Shares	% Assets	Change	Value
Driehaus capital management	1.40M	0.01%	1.40M	$1.08M
Adage capital partners gp	1.00M	0.00%	1.00M	$933.70K
Sio capital management	1.00M	0.26%	1.00M	$933.70K
Velan capital investment management lp	70.00K	0.06%	70.00K	$65.36K
Susquehanna group, llp	45.12K	-	45.12K	$42.13K

Sold Out

Holder	Change
Ifp advisors	-8.00
Nelson, van denburg & campbell wealth management group	-10.00
Qube research	-54.00
Ica group wealth management	-55.00
Capital performance advisors llp	-146.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	83	-	46,400,658	-2.45%	37	0.83%	29	-21.62%	28	33.33%
Dec 31, 2024	28	-63.16%	10,144,389	-73.85%	14	0.48%	13	-69.05%	7	-53.33%
Sep 30, 2024	76	2.70%	38,794,655	0.78%	54	1.84%	42	16.67%	15	-40.00%
Jun 30, 2024	74	-8.64%	38,492,740	-9.60%	54	1.50%	36	-5.26%	25	4.17%
Mar 31, 2024	81	5.19%	42,579,420	-3.51%	60	1.55%	38	-7.32%	24	41.18%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.79M	2.52%	-
Vanguard Total Stock Mkt Idx Inv	1.79M	2.52%	-
Kennedy Micro Cap	1.04M	1.46%	-64.12K
Vanguard Institutional Extnd Mkt Idx Tr	819.59K	1.15%	-
Fidelity Small Cap Index	578.63K	0.81%	-887.00
State St Russell Sm/Mid Cp® Indx NL Cl C	525.80K	0.74%	-
State St Russell Sm/Mid Cp® Indx SL Cl I	525.80K	0.74%	-
MEDICAL BioHealth EUR Acc	503.85K	0.71%	-
Kennedy Micro Cap Opportunities	465.48K	0.65%	82.64K
iShares Biotechnology ETF	393.77K	0.55%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 26, 2025	ALEXANDER MARGARET A.	President and COO	Sell	$2.96K
Feb 26, 2025	Rona Jeffrey A	CBFO	Sell	$2.19K
Jan 27, 2025	ALEXANDER MARGARET A.	President and COO	Buy	$4.97K
Mar 18, 2024	LEVIN JEREMY M	CEO	Buy	$50.36K
Sep 12, 2022	Tardio Jason	Chief Operating Officer	Sell	$37.29K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	1	2
2024 Q4	-	-
2024 Q3	-	-
2024 Q1	1	-
2023 Q4	-	-

OVID Ownership FAQ

Who Owns Ovid Therapeutics?

Ovid Therapeutics shareholders are primarily institutional investors at 37.12%, followed by 16.31% insiders and 46.57% retail investors. The average institutional ownership in Ovid Therapeutics's industry, Biotech Stocks , is 63.94%, which Ovid Therapeutics falls below.

Who owns the most shares of Ovid Therapeutics?

Ovid Therapeutics’s largest shareholders are Takeda pharmaceutical (7.53M shares, 10.61%), Rubric capital management lp (5.32M shares, 7.49%), and Blackrock (3.99M shares, 5.65%). Together, they hold 23.75% of Ovid Therapeutics’s total shares outstanding.

Does Blackrock own Ovid Therapeutics?

Yes, BlackRock owns 5.65% of Ovid Therapeutics, totaling 3.99M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.07M$. In the last quarter, BlackRock decreased its holdings by -203K shares, a -4.84% change.

Who is Ovid Therapeutics’s biggest shareholder by percentage of total assets invested?

Takeda pharmaceutical is Ovid Therapeutics’s biggest shareholder by percentage of total assets invested, with 26.40% of its assets in 7.53M Ovid Therapeutics shares, valued at 7.01M$.

Who is the top mutual fund holder of Ovid Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Ovid Therapeutics shares, with 2.52% of its total shares outstanding invested in 1.79M Ovid Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools